+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer

Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer

European Journal of Surgical Oncology 19(3): 273-278

The prognosis of 84 patients with advanced ovarian cancer who received the same regimen of postoperative chemotherapy but who received different surgical procedures, was evaluated retrospectively. Of those patients, 41 underwent cytoreductive surgery with lymphadenectomy, including removal of the para-aortic nodes (group A). The other 43 patients received hysterectomy, bilateral salpingoophorectomy and omentectomy (group B). Overall the patients in group A showed a significantly greater survival than those in group B. The performance of lymphadenectomy in patients with positive nodes improves the prognosis to equal that of patients with negative nodes. It is suggested that cytoreductive surgery with lymphadenectomy may be useful for the improvement of the prognosis of patients with advanced ovarian cancer.

(PDF emailed within 1 workday: $29.90)

Accession: 046009027

Download citation: RISBibTeXText

PMID: 8314386

Related references

Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecologic Oncology 56(3): 328-337, 1995

Retroperitoneal lymphadenectomy, including the para-aortic nodes in patients with stage III ovarian cancer. American Journal of Clinical Oncology 17(3): 230-233, 1994

Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer. Oncology Reports 22(3): 509-514, 2009

Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecologic Oncology 56(3): 345-352, 1995

Recurrent ovarian cancer with multiple lymph nodes metastases successfully treated with lymphadenectomy as secondary cytoreductive surgery: A case report. International Journal of Surgery Case Reports 5(7): 412-415, 2014

Maximum effort in the management of ovarian cancer, including pelvic and para-aortic lymphadenectomy. Australian & New Zealand Journal of Obstetrics & Gynaecology 32(1): 50-53, 1992

Comparison of pelvic and para-aortic lymphadenectomy versus para-aortic lymphadenectomy alone for locally advanced FIGO stage IB2 to IIB cervical cancer using a propensity score matching analysis: Results from the FRANCOGYN study group. European Journal of Surgical Oncology 44(12): 1921-1928, 2018

Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Hepato-Gastroenterology 54(74): 634-638, 2007

Spleen- and pancreas-preserving total gastrectomy with superextended lymphadenectomy including dissection of the para-aortic lymph nodes for gastric cancer. Journal of Surgical Oncology 63(4): 268-270, 1996

Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes. Chinese Medical Journal 127(3): 435-441, 2015

Impact of Pelvic and Para-aortic Lymphadenectomy in Advanced Ovarian Cancer After Neoadjuvant Chemotherapy. Anticancer Research 35(10): 5503-5509, 2016

Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer. American Journal of Clinical Oncology 22(5): 481-484, 1999

Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. International Journal of Gynecological Cancer 7(1): 18-26, 1997

Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases. Oncotarget 8(31): 51840-51847, 2017

Standardization of cytoreductive surgery is a precondition for clinical trials of ovarian cancer including cytoreductive surgery and/or neoadjuvant chemotherapy. Gynecologic Oncology 125(2): 510-510, 2012